$145.04 -4.87 (%) Amgen Inc - NASDAQ

Feb. 5, 2016 | 04:00 PM

Partner Headlines

  1. Leerink Is Back On Board The Biotech Train

    Benzinga | Feb. 5, 2016 | 10:32AM EST
  2. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD | Feb. 5, 2016 | 09:16AM EST
  3. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus | Feb. 2, 2016 | 12:32PM EST
  4. Maybe Some Good News For A Big Biotech ETF

    Benzinga | Jan. 29, 2016 | 08:39AM EST
  5. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga | Jan. 28, 2016 | 16:52PM EST
  6. Earnings Recap For January 28

    Benzinga | Jan. 28, 2016 | 16:34PM EST
  7. FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501

    Benzinga | Jan. 25, 2016 | 17:21PM EST
  8. Regeneron Is Now A Sell For Chardan

    Benzinga | Jan. 25, 2016 | 08:40AM EST
  9. Big Earnings Expectations For Big Biotech

    Benzinga | Jan. 24, 2016 | 16:55PM EST
  10. Amgen's Vectibix, Best Supportive Care Improves Overall Survival vs BSC In Chemorefractory KRAS, RAS Wild-Type mCRC

    Benzinga | Jan. 23, 2016 | 15:57PM EST
  11. Amgen's Repatha) Approved in Japan as First PCSK9 Inhibitor for Treatment of High Cholesterol

    Benzinga | Jan. 22, 2016 | 04:21AM EST
  12. Medicines Company Spikes On Report Of Possible Sale

    IBD | Jan. 20, 2016 | 12:59PM EST
  13. Jim Cramer Likes Amgen

    Benzinga | Jan. 20, 2016 | 06:40AM EST
  14. Write A Prescription For This Healthcare ETF

    Benzinga | Jan. 15, 2016 | 08:24AM EST
  15. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD | Jan. 14, 2016 | 16:29PM EST
  16. Stocks, Mutual Funds Rose In Q4 Despite Dec. Woes

    IBD | Jan. 8, 2016 | 18:22PM EST
  17. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga | Jan. 7, 2016 | 06:35AM EST
  18. 3 Potential Blockbuster Drugs Launching in 2016

    IBD | Jan. 6, 2016 | 09:42AM EST
  19. Mid-Afternoon Market Update: Netflix Drops Following Baird Downgrade; Lululemon Shares Rise

    Benzinga | Jan. 4, 2016 | 15:01PM EST
  20. Mid-Day Market Update: Baxalta Shares Surge Amid Report Of Shire Interest; Canadian Solar Shares Slide

    Benzinga | Jan. 4, 2016 | 12:15PM EST
  21. Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers 17,400 Vehicles in Fourth Quarter

    Benzinga | Jan. 4, 2016 | 10:10AM EST
  22. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 4, 2016 | 08:13AM EST
  23. Alan Fournier Sells GM, Buys Molson Coors Brewing

    GuruFocus | Jan. 3, 2016 | 13:24PM EST
  24. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD | Dec. 30, 2015 | 14:16PM EST
  25. Dividend Growth Skids To Halt For S&P 500

    IBD | Dec. 30, 2015 | 08:02AM EST
  26. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus | Dec. 23, 2015 | 14:24PM EST
  27. Benzinga's M&A Chatter for Monday December 21, 2015

    Benzinga | Dec. 21, 2015 | 19:59PM EST
  28. Big Cap 20 Stocks Setting Up In Bases

    IBD | Dec. 21, 2015 | 18:31PM EST
  29. Analyzing Amgen's Dividend Hike

    GuruFocus | Dec. 21, 2015 | 00:03AM EST
  30. 3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

    Benzinga | Dec. 18, 2015 | 14:10PM EST
  31. Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016

    Benzinga | Dec. 18, 2015 | 10:52AM EST
  32. EC Approves Amgen's IMLYGIC as First Oncolytic Immunotherapy In Europe

    Benzinga | Dec. 18, 2015 | 04:25AM EST
  33. 4 Top Dividend Plays To Help Cure Stock Price Blues

    IBD | Dec. 17, 2015 | 17:14PM EST
  34. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD | Dec. 17, 2015 | 17:08PM EST
  35. Allergan Among Health Care Holdings in Alan Fournier's Portfolio

    GuruFocus | Dec. 15, 2015 | 14:33PM EST
  36. Benzinga's Top Upgrades

    Benzinga | Dec. 15, 2015 | 08:59AM EST
  37. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 15, 2015 | 08:26AM EST
  38. Amgen Shares Move Higher Following Morgan Stanley Upgrade To Overweight

    Benzinga | Dec. 15, 2015 | 07:53AM EST
  39. Amgen Submits Application to EMA To Expand Indication Of Kyprolis For The Treatment Of Relapsed Multiple Myeloma

    Benzinga | Dec. 5, 2015 | 10:26AM EST
  40. Amgen Announces New Analyses Presented At #ASH2015 Demonstrate Potential Of Kyprolis As Backbone Therapy In Multiple Myeloma

    Benzinga | Dec. 5, 2015 | 10:25AM EST
  41. Amgen Announces Pivotal Head-To-Head ENDEAVOR Study Results Published in The Lancet Oncology Demonstrate Superiority of Kyprolis Combination Over Velcade Combination

    Benzinga | Dec. 5, 2015 | 10:24AM EST
  42. Amgen, Merck target cancer

    IBD | Dec. 4, 2015 | 18:37PM EST
  43. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD | Dec. 4, 2015 | 13:46PM EST
  44. LinkedIn, Palo Alto, Regeneron Profit Estimates Rising

    IBD | Dec. 4, 2015 | 08:02AM EST
  45. Application for Amgen's Biosimilar Candidate to Humira, Submitted to EMA

    Benzinga | Dec. 4, 2015 | 04:07AM EST
  46. Benzinga's M&A Chatter for Tuesday December 1, 2015

    Benzinga | Dec. 1, 2015 | 19:29PM EST
  47. Biotechs Weaken, But These Names Have Bullish Charts

    IBD | Nov. 25, 2015 | 17:19PM EST
  48. EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia

    Benzinga | Nov. 24, 2015 | 04:20AM EST
  49. CVS Makes Amgen New BFF

    IBD | Nov. 23, 2015 | 18:42PM EST
  50. CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi

    IBD | Nov. 23, 2015 | 16:06PM EST
Trading Center